Provided by Tiger Trade Technology Pte. Ltd.

CervoMed

2.61
-0.1200-4.40%
Post-market: 2.670.0600+2.30%19:58 EDT
Volume:448.46K
Turnover:1.18M
Market Cap:39.46M
PE:-0.82
High:2.82
Open:2.82
Low:2.55
Close:2.73
52wk High:11.25
52wk Low:2.13
Shares:15.12M
Float Shares:11.20M
Volume Ratio:0.97
T/O Rate:4.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1959
EPS(LYR):-2.9824
ROE:-107.62%
ROA:-60.80%
PB:1.72
PE(LYR):-0.88

Loading ...

Company Profile

Company Name:
CervoMed
Exchange:
NASDAQ
Establishment Date:
2010
Employees:
15
Office Location:
20 Park Plaza,Suite 424,Boston,Massachusetts,United States
Zip Code:
02116
Fax:
- -
Introduction:
CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Directors

Name
Position
John Alam
Chief Executive Officer and Director and President
Joshua S. Boger
Chair, Director
David Quigley
Director
Frank Zavrl
Director
Jane Hollingsworth
Director
Jeff Poulton
Director
Marwan Sabbagh
Director
Sylvie Gregoire
Director

Shareholders

Name
Position
John Alam
Chief Executive Officer and Director and President
William Elder
Chief Financial Officer and General Counsel
Kelly Blackburn
Executive Vice President, Clinical Development
Marco Verwijs
Executive Vice President, Technical Operations
Mark De Rosch
Executive Vice President, Regulatory and Govt. Affairs and Program Mgmt
Matthew Winton
Chief Commercial and Business Officer